Processa Pharmaceuticals

Processa Pharmaceuticals

Processa Pharmaceuticals incorporated in 2011 and reorganized through a reverse merger in 2021, taking the ticker PCSA on Nasdaq. George Ng has served as CEO since 2017, steering a lean operation that deliberately avoids broad pipelines in favor of two core programs. The firm's founding thesis targets the side-effect burden of existing chemotherapy agents, a problem oncologists manage daily but few drug developers prioritize. Strategy centers on Next Generation Capecitabine — partnered with a South Korean manufacturer — and PCS12852, a treatment for gastroparesis licensed from a Japanese originator. Both programs live in Phase 2, meaning all value sits in data readouts, not revenue. Processa does not operate as a fund or manage outside capital; it burns operating cash like every pre-revenue biotech, funding itself through periodic public-market raises. Team size remains small — SEC filings typically list under 10 named officers and directors — with R&D run by Dr. David Young. No significant physical footprint beyond the Hanover headquarters and no disclosed capital-deployment headcount. The firm does not disclose AUM; its last reported cash position was roughly $6 million as of early 2025. In March 2025: Announced a $2 million registered direct offering to extend its operational runway (per SEC filing, March 2025). Processa's structural differentiator is its inversion of the standard oncology-development model. Instead of chasing a novel target, it reformulates drugs with decades of human safety data — a strategy that cuts Phase 1 failure risk but demands a high-conviction bet on differentiated tolerability. Success depends entirely on whether a less-toxic version of an established agent can demonstrate meaningful improvement in a trial setting where the comparator is already widely available and generic.